Kiniksa Pharmaceuticals International clinical trials we track

Check company identity source

Phase 2 / 3 2 trials

Phase 2 2 trials

TrialDrugs studiedStatusPrimary completion
Transition to KPL-387 Monotherapy Dosing & Administration StudyNCT07288216KPL-387Recruiting2027-12-31Estimated
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseNCT06531395AbiprubartTerminated2025-03-06Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216 · Kiniksa Pharmaceuticals International, plc

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From first administration of study drug up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months. After: Measure: Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 Time frame: From baseline up to Week 16 Measure: Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE. Time frame: Up to 24 Months.

Planned enrollment increased by 40 participants

Before: 80 participants (planned). After: 120 participants (planned).

Check registry source